Nordic Nanovector to Discontinue P-IIb (PARADIGME) Trial of Betalutin in 3L Treatment of Relapsed and Anti-CD20 Refractory Follicular Lymphoma
- The Board of Directors has decided to cease the P-IIb (PARADIGME) trial, following a thorough examination and independent data evaluation of (PARADIGME) trial and a subsequent request for regulatory agency interaction. There will be no more patients enrolled in the trial
- Betalutin has continued to exhibit an appealing safety profile and positive signs of efficacy in some patients at a dose of 15 MBq/kg after a pre-dose of 40mg lilotomab while the observed profile does not fully meet the objectives set out for (PARADIGME) study
- The Board has also agreed to immediately begin reorganizing the company to lower expenses to support essential activities related to pipeline development
Ref: PRNewswire | Image: Nordic Nanovector
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.